ネモリズマブの成功 糖尿病患者の耐性反応性穿孔性コラーゲノスの治療
Asuka Oikawa1, Ken Muramatsu1, Kazuki Watanabe1
1Dermatology, Hokkaido University Hospital, Sapporo, JPN.
Cureus
|August 29, 2025
まとめ
糖尿病に関連した稀な皮膚疾患である得られた反応性開口性コラーゲノーシス (ARPC) は,しばしば激しいを起こす. 抗IL-31抗体であるネモリズマブを使用した新しい治療法は,ARPC患者の症状を効果的に解消しました.
科学分野:
- 皮膚科
- 免疫学
- 内分泌学
背景:
- 既得反応性穴開き性コラーゲノシス (ARPC) は,糖尿病と頻繁に関連している希少な皮膚病です.
- トランセピダーマールコラーゲンの除去と重大なが特徴です.
研究 の 目的:
- 制御不良の糖尿病患者のARPC症例を報告する.
- 耐火性ARPCの管理における,抗IL-31受容体A単体抗体のネモリズマブの有効性を評価する.
主な方法:
- ARPCの77歳の日本人女性の症例報告です.
- 組織病理学的検査で診断が確認された.
- 治療法:皮下ネモリズマブ (60 mg 4週間に1回)
主要な成果:
- 患者は完全にを消した.
- 治療後2ヶ月以内に皮膚病変の顕著な平ら化が観察されました.
- 皮質病理学では コラーゲンの除去と皮膚の炎症性浸透が示されました
結論:
- 耐火性ARPCに対するネモリズマブによるIL-31標的治療は有望である.
- ネモリズマブは,選択されたARPC症例において有効な治療法である可能性があります.
- ARPCにおけるネモリズマブの有効性と安全性を確認するには,さらなる研究が必要である.
関連する概念動画
Chronic Pancreatitis II: Collaborative Care
128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
128
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Diabetes: Management and Pharmacotherapy
354
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
354
Nephrotic Syndrome II : Assessment and Medical Management
21
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
21


